FDA — authorised 19 January 2001
- Application: BLA103949
- Marketing authorisation holder: SCHERING
- Local brand name: PEGINTRON
- Indication: VIAL
- Status: approved
🇺🇸 PEG-IFN alfa-2b in United States
FDA authorised PEG-IFN alfa-2b on 19 January 2001
Marketing authorisations
FDA
- Status: approved
PEG-IFN alfa-2b in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is PEG-IFN alfa-2b approved in United States?
Yes. FDA authorised it on 19 January 2001; FDA has authorised it.
Who is the marketing authorisation holder for PEG-IFN alfa-2b in United States?
SCHERING holds the US marketing authorisation.